A FDA advisory panel voted that benefits of Grail’s Galleri test outweigh risks for people 50+, while flagging uncertain evidence that earlier detection will improve long-term outcomes and urging continued evaluation.
Effectiveness was contested: six members voted yes and four voted no on whether the test is effective.
Galleri detects cancer-specific methylation patterns in cell-free DNA and is intended to supplement—not replace—recommended screenings.
Panelists emphasized the need for long-term outcome data and robust post-market surveillance if approved.
A FDA advisory panel — the Medical Devices Advisory Committee's Molecular and Clinical Genetics Panel — reviewed Grail's premarket approval application for Galleri and voted that the benefits outweigh the potential risks for adults aged 50 years or older. The committee's votes were: unanimous that the test is safe, split 6–4 on efficacy, and 7–2 with one abstention that benefits outweigh risks.
Supporters pointed to the test's potential to find cancers that currently lack screening options. Panel member Danil V. Makarov, MD, said the ability to screen for cancers that previously were not screenable "would be a major contribution." Victor van Berkel, MD, PhD, also voted in favor but described his vote as hopeful: he said the test may prove beneficial over time for cancers without good screening tests, though that benefit is not yet proven.
Skeptical and cautious members questioned whether detecting more cancer signals now will translate into better long-term clinical outcomes. Multiple panelists called for stronger evidence that earlier detection via Galleri reduces advanced-stage disease or mortality.
Regulatory and practical implications
This is the first premarket approval application for a multicancer early detection (MCED) test submitted to FDA. If FDA follows the advisory panel and approves Galleri for the 50+ population, broader insurance coverage could follow. Several speakers during the day-long meeting included physicians, advocates, and patients who shared cases where Galleri signals preceded diagnosis of early-stage cancer.
Panelists who voted in favor urged robust post-market surveillance to confirm real-world benefit and to monitor downstream testing and outcomes. Those who voted against or withheld full endorsement highlighted the need for long-term outcome data showing that earlier detection with Galleri reduces late-stage disease or improves survival.
The advisory panel's recommendation favors conditional adoption for adults 50 and older because of potential to detect cancers with no current screening. The vote was not unanimous on effectiveness, and the panel called for careful follow-up, evidence collection, and clear clinical pathways for managing positive results.
FDA advisory panel voted in favor of GRAIL's Galleri multi-cancer early detection test for adults 50 and older, supporting its safety and benefit-risk profile
Panel members said the first-of-a-kind blood test should not be used to replace medical guideline-recommended cancer screenings, however.
THURSDAY, Sept. 24, 2026 — A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works. The test...
Federal health advisers on Wednesday endorsed a blood test designed to spot signs of various cancers in apparently healthy people while warning that it’s far from clear how well the technology works. Grail Inc.’s Galleri test doesn’t diagnose cancer but instead, with a single blood draw, looks for a signal that someone
Efforts to detect multiple cancers through a single blood draw are gathering momentum after US regulators endorsed the technology for the first time, although experts say wider adoption in Hong Kong still faces challenges as doctors remain cautious about its clinical value. In a landmark decision for the emerging field
Open the app view to save this story, compare related coverage, and continue from the same source.